Influenza A H1N1 influenza virus first drug resistance
June 20, 2021
The first resistance of influenza A H1N1 influenza virus Swiss Roche Pharmaceutical Company confirmed on June 29 that a Danish H1N1 influenza patient in Denmark had developed resistance to the company's anti-influenza drug "Duffy". This is the first time scientists have detected the resistance mutation of the H1N1 influenza virus to "Duffy". David Reddy, a spokesman for Roche Pharmaceuticals, said that this patient showed resistance to "Duffy" during the treatment process, and the company is currently investigating countermeasures. Reddy believes that the clinical trials for "Duffy" show that the proportion of cases that show resistance to this drug should be within 0.5%. Although Denmark has the first drug resistance mutation, the company has long expected this development. The current situation does not mean that other influenza A H1N1 viruses have developed drug resistance. GlaxoSmithKline's "Leganqing" and Roche Pharmaceutical's "Duffy" capsules are considered to be anti-influenza drugs that can effectively inhibit the H1N1 influenza virus. According to the Danish health department, after discovering that this patient had drug resistance, the hospital replaced "Daffei" with "Leganqing" in the treatment process, and no new drug resistance was found. The patient is now in stable condition and has no flu symptoms. The World Health Organization announced on June 11 that raising the influenza pandemic alert level to level 6 means officially declaring the arrival of an influenza pandemic. Some experts worry that the H1N1 influenza virus may mix with the seasonal influenza virus that is still circulating, and may pose a greater threat to human health.
The above is the Influenza A H1N1 influenza virus first drug resistance we have listed for you. You can submit the following form to obtain more industry information we provide for you.
You can visit our website or contact us, and we will provide the latest consultation and solutions
June 20, 2021
